Abstract
Neutrophil elastase (NE) plays an important role in the progression of acute lung injury (ALI). Sivelestat sodium hydrate (Sivelestat) is a highly specific synthetic inhibitor of NE. High mobility group box 1 (HMGB1) is one of the key mediators in the development of sepsis. The aim of this study was to evaluate the effect of sivelestat and to determine whether it can reduce lipopolysaccharide (LPS)-induced acute lung injury in rats. Rats were randomly divided into a negative control group, an LPS-induced sepsis group, and a group treated with sivelestat prior to LPS administration. Animals in the sivelestat group received a bolus of 10 mg/kg of sivelestat injected into the intraperitoneal cavity before the LPS treatment. Furthermore, rats were administered sivelestat at 0, 1, 3, and 6 h following LPS treatment. We measured cytokine and HMGB1 levels in the serum after the induction of sepsis. In addition, we observed histopathology, wet/dry weight ratio, inducible nitric oxide synthase and HMGB1 expression in the lung tissue. Lung histopathology was significantly improved in the sivelestat group compared to the LPS group. Serum and pulmonary HMGB1 levels were lower over time among sivelestat-treated animals. Furthermore, inhibition of NF-κB activity was observed with the administration of sivelestat. These results suggest that sivelestat reduces LPS-induced lung injury at least partially by inhibiting inflammation and NF-κB activity.
Similar content being viewed by others
References
Schlichting, D., and J. S. McCollam. 2007. Recognizing and managing severe sepsis: a common and deadly threat. South Med. J. 100(6):594–600.
Costa, E. L., I. A. Schettino, and G. P. Schettino. 2006. The lung in sepsis: guilty or innocent? Endocr. Metab. Immune. Disord. Drug Targets 6(2):213–216.
Andrews, P., E. Azoulay, M. Antonelli, L. Brochard, C. Brun-Buisson, G. Dobb, J. Y. Fagon, H. Gerlach, J. Groeneveld, J. Mancebo, P. Metnitz, S. Nava, J. Pugin, M. Pinsky, P. Radermacher, C. Richard, and R. Tasker. 2006. Year in review in intensive care medicine, 2005. II. Infection and sepsis, ventilator-associated pneumonia, ethics, haematology and haemostasis, ICU organisation and scoring, brain injury. Intensive. Care Med. 32:380–390.
Andrews, P., E. Azoulay, M. Antonelli, L. Brochard, C. Brun-Buisson, G. Dobb, J. Y. Fagon, H. Gerlach, J. Groeneveld, J. Mancebo, P. Metnitz, S. Nava, J. Pugin, M. Pinsky, P. Radermacher, C. Richard, R. Tasker, and B. Vallet. 2005. Year in review in intensive care medicine, 2004. I. Respiratory failure, infection, and sepsis. Intensive. Care Med. 31:28–40.
Weiss, S. J. 1989. Tissue destruction by neutrophils. N. Engl. J. Med. 320:365–376.
Vender, R. L. 1996. Therapeutic potential of neutrophil-elastase inhibition in pulmonary disease. J. Invest. Med. 44:531–539.
Moreas, T. J., C. W. Chow, and G. P. Downey. 2003. Proteases and lung injury. Crit. Care Med. 31:S189–S194.
Kawabata, K., M. Suzuki, M. Sugitani, K. Imaki, M. Toda, and T. Miyamoto. 1991. ONO-5046, a novel inhibitor of human neutrophil elastase. Biochem. Biophys. Res. Commun. 177:814–820.
Bellomo, R., S. Uchino, T. Naka, and L. Wan. 2004. Hidden evidence to the West: multicentre, randomised, controlled trials in sepsis and systemic inflammatory response syndrome in Japanese journals. Intensive. Care Med. 30:911–917.
Sakamaki, F., A. Ishizaka, T. Urano, K. Sayama, H. Nakamura, T. Terashima, Y. Waki, S. Tasaka, N. Hasegawa, K. Sato, N. Nakagawa, T. Obata, and M. Kanazawa. 1996. Effect of a specific neutrophil elastase inhibitor, ONO-5046, on endotoxin-induced acute lung injury. Am. J. Respir. Crit. Care Med. 153(1):391–397.
Wakayama, F., I. Fukuda, Y. Suzuki, and N. Kondo. 2007. Neutrophil elastase inhibitor, sivelestat, attenuates acute lung injury after cardiopulmonary bypass in the rabbit endotoxemia model. Ann. Thorac. Surg. 83(1):153–160.
Wang, H., O. Bloom, M. Zhang, J. M. Vishnubhakat, M. Ombrellino, J. Che, A. Frazier, H. Yang, S. Ivanova, L. Borovikova, K. R. Manogue, E. Faist, E. Abraham, J. Andersson, U. Andersson, P. E. Molina, N. N. Abumrad, A. Sama, and K. J. Tracey. 1999. HMG-1 as a late mediator of endotoxin lethality in mice. Science 285:248–251.
Ueno, H., T. Matsuda, S. Hashimoto, F. Amaya, Y. Kitamura, M. Tanaka, A. Kobayashi, I. Maruyama, S. Yamada, N. Hasegawa, J. Soejima, H. Koh, and A. Ishizaka. 2004. Contributions of high mobility group box protein in experimental and clinical acute lung injury. Am. J. Respir. Crit. Care Med. 170:1310–1316.
Yu, M., H. Wang, A. Ding, D. T. Golenbock, E. Latz, C. J. Czura, M. J. Fenton, K. J. Tracey, and H. Yang. 2006. HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock 26:174–179.
Park, J. S., F. Gamboni-Robertson, Q. He, D. Svetkauskaite, J. Y. Kim, D. Strassheim, J. W. Sohn, S. Yamada, I. Maruyama, A. Banerjee, A. Ishizaka, and E. Abraham. 2006. High Mobility Group Box 1 protein (HMGB1) interacts with multiple Toll like receptors. Am. J. Physiol. Cell Physiol. 290:917–924.
Sunden-Cullberg, J., A. Norrby-Teglund, and C. J. Treutiger. 2006. The role of high mobility group box-1 protein in severe sepsis. Curr. Opin. Infect. Dis. 19:231–236.
Hatada, T., H. Wada, T. Nobori, K. Okabayashi, K. Maruyama, Y. Abe, S. Uemoto, S. Yamada, and I. Maruyama. 2005. Plasma concentrations and importance of High Mobility Group Box protein in the prognosis of organ failure in patients with disseminated intravascular coagulation. Thromb. Haemost. 94:975–979.
Sunden-Cullberg, J., A. Norrby-Teglund, A. Rouhiainen, H. Rauvala, G. Herman, K. J. Tracey, M. L. Lee, J. Andersson, L. Tokics, and C. J. Treutiger. 2005. Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock. Crit. Care Med. 33:564–573.
Wang, H., H. Yang, C. J. Czura, A. E. Sama, and K. J. Tracey. 2001. HMGB1 as a late mediator of lethal systemic inflammation. Am. J. Respir. Crit. Care Med. 164:1768–1773.
Poltorak, A., X. He, I. Smirnova, M. Y. Liu, C. Van Huffel, X. Du, D. Birdwell, E. Alejos, M. Silva, C. Galanos, M. Freudenberg, P. Ricciardi-Castagnoli, B. Layton, and B. Beutler. 1998. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282:2085–2088.
Jiang, W., and D. S. Pisetsky. 2006. The role of IFN-alpha and nitric oxide in the release of HMGB1 by RAW 264.7 cells stimulated with polyinosinic-polycytidylic acid or lipopolysaccharide. J. Immunol. 1;177(5):3337–3343.
Wang, H., J. M. Vishnubhakat, O. Bloom, M. Zhang, M. Ombrellino, A. Sama, and K. J. Tracey. 1999. Proinflammatory cytokines (tumor necrosis factor and interleukin 1) stimulate release of high mobility group protein-1 by pituicytes. Surgery 126:389–392.
Murakami, K., R. McGuire, R. A. Cox, J. M. Jodoin, L. J. Bjertnaes, J. Katahira, L. D. Traber, F. C. Schmalstieg, H. K. Hawkins, D. N. Herndon, and D. L. Traber. 2002. Heparin nebulization attenuates acute lung injury in sepsis following smoke inhalation in sheep. Shock 18:236–241.
Tate, R. M., and J. E. Repine. 1983. Neutrophils and the adult respiratory distress syndrome. Am. Rev. Respir. Dis. 128:552–559.
Chandra, A., P. Enkhbaatar, Y. Nakano, L. D. Traber, and D. L. Traber. 2006. Sepsis: emerging role of nitric oxide and selectins. Clinics 61:71–76.
Bhatia, M., and S. Moochhala. 2004. Role of inflammatory mediators in the pathophysiology of acute respiratory distress syndrome. J. Pathol. 202:145–156.
Jiang, W., and D. S. Pisetsky. 2006. The role of IFN-alpha and nitric oxide in the release of HMGB1 by RAW 264.7 cells stimulated with polyinosinic–polycytidylic acid or lipopolysaccharide. J. Immunol. 177(5):3337–3343.
Schwartz, M. D., E. E. Moore, F. A. Moore, R. Shenkar, P. Moine, J. B. Haenel, and E. Abraham. 1996. Nuclear factor-kappa B is activated in alveolar macrophages from patients with acute respiratory distress syndrome. Crit. Care Med. 24:1285–1292.
Liu, S. F., and A. B. Malik. 2006. NF-kappa B activation as a pathological mechanism of septic shock and inflammation. Am. J. Physiol. Lung Cell Mol. Physiol. 290(4):L622–L645.
Pritts, T. A., M. R. Moon, Q. Wang, E. S. Hungness, A. L. Salzman, J. E. Fischer, and P. O. Hasselgren. 2000. Activation of NF-kappaB varies in different regions of the gastrointestinal tract during endotoxemia. Shock 14:118–122.
Kawai, T., O. Adachi, T. Ogawa, K. Takeda, and S. Akira. 1999. Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity. 11(1):115–122.
Adcock, I. M. 1997. Transcription factors as activators of gene transcription: AP-1 and NF-kappa B. Monaldi. Arch. Chest Dis. 52:178–186.
Kuwahara, I., E. P. Lillehoj, W. Lu, I. S. Singh, Y. Isohama, T. Miyata, and K. C. Kim. 2006. Neutrophil elastase induces IL-8 gene transcription and protein release through p38/NF-{kappa}B activation via EGFR transactivation in a lung epithelial cell line. Am. J. Physiol. Lung Cell Mol. Physiol. 291:L407–L416.
Acknowledgments
The authors wish to thank Dr. Tomohisa Uchida for giving us helpful advice and for scoring lung injuries.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hagiwara, S., Iwasaka, H., Togo, K. et al. A Neutrophil Elastase Inhibitor, Sivelestat, Reduces Lung Injury Following Endotoxin-Induced Shock in Rats by Inhibiting HMGB1. Inflammation 31, 227–234 (2008). https://doi.org/10.1007/s10753-008-9069-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10753-008-9069-z